Scientific publications

First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies

Dec 13, 2023 | Magazine: Clinical Genitourinary Cancer

María Dolores Fenor de la Maza  1 , Guillermo Villacampa  2 , Bernardino Miñana  3 , Guillermo Barbas Bernardos  3 , Guillermo Andrés  3 , Daniel Antonio González-Padilla  3 , Fernando Ramón de Fata  3 , Julián Sanz  4 , Mauricio Cambeiro  5 , Javier Aristu  5 , Alfonso Gúrpide  6 , Felipe Villacampa  3 , Jose Luis Pérez Gracia  6


The standard of care for the first-line management of metastatic urothelial carcinoma has been recently challenged, with the combination of pembrolizumab and enfortumab vedotin (P-EV) strongly arising as a practice-changing option from classical platinum-based chemotherapies.

With this paradigm shift on the horizon new questions, including the most suitable second line of treatment for these patients, and the role that the molecular characterization of these tumours will have when selecting these therapies will inevitably arise.

Furthermore, after the negative results of the Keynote 361 and IMvigor 130 trials, the combination of nivolumab with platinum-based chemotherapy followed by nivolumab maintenance (Nivo GC-Nivo) has also shown positive results when compared with chemotherapy alone. Translational studies at a molecular, cellular, and functional level will be key to better explain these discordant results.

In this Current Perspective, we discuss the potential impact of these results in clinical practice and propose specific guidance for prospective translational research.

CITATION  Clin Genitourin Cancer. 2023 Dec 13:S1558-7673(23)00267-7.  doi: 10.1016/j.clgc.2023.12.001